HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by de Benedictis, F. M. Articles by Capristo, A. Search for Related Content PubMed PubMed Citation Articles by de Benedictis, F. M. Articles by Capristo, A.

Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children

¹ Depts of Paediatrics, University of Perugia, Perugia, and ² University of Naples, Naples, Italy.

CORRESPONDENCE: F. M. de Benedictis, Dept of Paediatrics, "G. Salesi" Children's Hospital, Via Corridoni 11, 60123 Ancona, Italy. Fax: 39 715962234. E-mail: debenedictis{at}ao-salesi.marche.it

Keywords: Exercise-induced bronchoconstriction, montelukast, tolerance

Received: February 10, 2006
Accepted April 16, 2006

The effect over time of regular treatment with montelukast (MNT) in inhibiting exercise-induced bronchoconstriction (EIB) has never been evaluated in children. The aim of the present study was to examine the preventive effect of MNT against EIB in children at different time-points over a 4-week treatment period.

Thirty-two asthmatic children (aged 6–12 yrs) were enrolled in a double-blinded, randomised, parallel group design to receive a 4-week treatment with MNT (5 mg chewable tablets administered once daily in the evening) or placebo. Exercise challenge was performed at baseline and after 3, 7 and 28 days of treatment, 20–24 h after dosing.

MNT was significantly more protective than placebo against EIB at each time. The mean percentage drop of forced expiratory volume in one second (FEV₁) was 24.6, 13.6, 12.0 and 11.6 for MNT, and 24.4, 22.4, 21.8 and 21.0 for placebo, at baseline and after 3, 7 and 28 days, respectively. For each drug, no significant difference in the percentage drop of FEV₁ was found between different days.

Regular treatment with montelukast provided significant protection against exercise-induced bronchoconstriction in asthmatic children over a 4-week period with no tolerance to the bronchoprotective effect.

This article has been cited by other articles:

				E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al. Global strategy for asthma management and prevention: GINA executive summary Eur. Respir. J., January 1, 2008; 31(1): 143 - 178. [Abstract] [Full Text] [PDF]

				G. Philip, D. S. Pearlman, C. Villaran, C. Legrand, T. Loeys, R. B. Langdon, and T. F. Reiss Single-Dose Montelukast or Salmeterol as Protection Against Exercise-Induced Bronchoconstriction Chest, September 1, 2007; 132(3): 875 - 883. [Abstract] [Full Text] [PDF]

				F. Hakim, D. Vilozni, A. Adler, G. Livnat, A. Tal, and L. Bentur The Effect of Montelukast on Bronchial Hyperreactivity in Preschool Children Chest, January 1, 2007; 131(1): 180 - 186. [Abstract] [Full Text] [PDF]